학술논문

Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
Document Type
Article
Source
In The Lancet 5-11 March 2022 399(10328):909-923
Subject
Primary Research
Articles
Language
ISSN
0140-6736